"10.1371_journal.pone.0103091","plos one","2014-08-13T00:00:00Z","David S Boyle; Ruth McNerney; Hwee Teng Low; Brandon Troy Leader; Ailyn C PÃ©rez-Osorio; Jessica C Meyer; Denise M O'Sullivan; David G Brooks; Olaf Piepenburg; Matthew S Forrest","Program for Appropriate Technology in Health, Seattle, WA, United States of America; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom; Washington State Department of Health, Public Health Laboratories, Shoreline, WA, United States of America; TwistDx Limited, Cambridge, United Kingdom","Conceived and designed the experiments: DSB RM APO DGB OP MSF. Performed the experiments: DSB HTL BTL APO DMO JCM MSF. Analyzed the data: DSB RM MSF. Contributed reagents/materials/analysis tools: DSB RM APO MSF. Contributed to the writing of the manuscript: DSB RM MSF.","JCM, DGB, OP, and MSF are employed by TwistDx, and have a stake in the success of its technology. TwistDx is one of the funders of this study and is a UK-based company, with a commercial interest in the use of the RPA technology for the detection of hospital-acquired pathogens. TwistDx Ltd, is the developer and manufacturer of RPA technology and is part of the of the Alere group of companies. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. DSB, BTL, APO, RM, HTL, and DOS have no financial interests in this technology.","2014","08","David S Boyle","DSB",10,TRUE,6,7,3,NA,TRUE,TRUE,FALSE,0,NA,FALSE
